[
  {
    "ts": null,
    "headline": "Why West Pharmaceutical Services Stock Was Blasting Higher on Thursday",
    "summary": "The company crushed analyst profitability estimates, both for its trailing quarter and for its full-year guidance.",
    "url": "https://finnhub.io/api/news?id=f16f3278d4c02ff6be994ddfe11cbb8238e7d28ae5f7a1f1169ca82d71118883",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761250872,
      "headline": "Why West Pharmaceutical Services Stock Was Blasting Higher on Thursday",
      "id": 137218220,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "The company crushed analyst profitability estimates, both for its trailing quarter and for its full-year guidance.",
      "url": "https://finnhub.io/api/news?id=f16f3278d4c02ff6be994ddfe11cbb8238e7d28ae5f7a1f1169ca82d71118883"
    }
  },
  {
    "ts": null,
    "headline": "Why Are West Pharmaceutical Services (WST) Shares Soaring Today",
    "summary": "Shares of healthcare products company West Pharmaceutical Services (NYSE:WST) jumped 12.3% in the afternoon session after the company reported strong third-quarter 2025 results that surpassed analyst estimates and raised its full-year financial forecast.",
    "url": "https://finnhub.io/api/news?id=babc42aa818d0fc9507a2ec38b7d3f5a8d46a2962066bac889e1b40e50c998b8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761249051,
      "headline": "Why Are West Pharmaceutical Services (WST) Shares Soaring Today",
      "id": 137218221,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "Shares of healthcare products company West Pharmaceutical Services (NYSE:WST) jumped 12.3% in the afternoon session after the company reported strong third-quarter 2025 results that surpassed analyst estimates and raised its full-year financial forecast.",
      "url": "https://finnhub.io/api/news?id=babc42aa818d0fc9507a2ec38b7d3f5a8d46a2962066bac889e1b40e50c998b8"
    }
  },
  {
    "ts": null,
    "headline": "West Pharmaceutical Services Inc (WST) Q3 2025 Earnings Call Highlights: Strong Organic Growth ...",
    "summary": "West Pharmaceutical Services Inc (WST) reports a robust third quarter with increased revenue and EPS, while setting a positive trajectory for future growth.",
    "url": "https://finnhub.io/api/news?id=c17f641d8601c67bb36b7f971ff00590abbbf5ec6e22f49fd2cd1e0887bbb3f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761246193,
      "headline": "West Pharmaceutical Services Inc (WST) Q3 2025 Earnings Call Highlights: Strong Organic Growth ...",
      "id": 137218222,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "West Pharmaceutical Services Inc (WST) reports a robust third quarter with increased revenue and EPS, while setting a positive trajectory for future growth.",
      "url": "https://finnhub.io/api/news?id=c17f641d8601c67bb36b7f971ff00590abbbf5ec6e22f49fd2cd1e0887bbb3f0"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why You Should Add OPKO Health Stock to Your Portfolio",
    "summary": "OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks.",
    "url": "https://finnhub.io/api/news?id=9fd343a36ba29c1f95b71490c078c5f44dbd60338052c94af676e8a26def8924",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761242160,
      "headline": "Here's Why You Should Add OPKO Health Stock to Your Portfolio",
      "id": 137218223,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks.",
      "url": "https://finnhub.io/api/news?id=9fd343a36ba29c1f95b71490c078c5f44dbd60338052c94af676e8a26def8924"
    }
  },
  {
    "ts": null,
    "headline": "WST Stock Up on Q3 Earnings Beat, EPS View Raised on Demand & FX Benefit",
    "summary": "West Pharmaceutical's strong Q3 beat and raised EPS outlook highlight robust demand, FX tailwinds, and solid growth in Proprietary Products.",
    "url": "https://finnhub.io/api/news?id=4af80ee297e443f73561a960866f5e3a9431448bfafc1de3eb83a7e94bee72e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761238080,
      "headline": "WST Stock Up on Q3 Earnings Beat, EPS View Raised on Demand & FX Benefit",
      "id": 137216518,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "West Pharmaceutical's strong Q3 beat and raised EPS outlook highlight robust demand, FX tailwinds, and solid growth in Proprietary Products.",
      "url": "https://finnhub.io/api/news?id=4af80ee297e443f73561a960866f5e3a9431448bfafc1de3eb83a7e94bee72e0"
    }
  },
  {
    "ts": null,
    "headline": "What Makes West Pharmaceutical Services (WST) a Prospective Investment?",
    "summary": "Upslope Capital Management, an investment management company, released its third-quarter investor letter. A copy of the letter can be downloaded here. The third quarter was a strong one for the fund despite unusual volatility in the macro environment. The fund returned +8.8% (net) in Q3 compared to +5.5% and +3.8% for the S&P Midcap 400 […]",
    "url": "https://finnhub.io/api/news?id=8c7a81b7cd04e92d0ba64506bf6776fc4b9284f4e23df0e955a0246724d7f0b8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761234515,
      "headline": "What Makes West Pharmaceutical Services (WST) a Prospective Investment?",
      "id": 137218225,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "Upslope Capital Management, an investment management company, released its third-quarter investor letter. A copy of the letter can be downloaded here. The third quarter was a strong one for the fund despite unusual volatility in the macro environment. The fund returned +8.8% (net) in Q3 compared to +5.5% and +3.8% for the S&P Midcap 400 […]",
      "url": "https://finnhub.io/api/news?id=8c7a81b7cd04e92d0ba64506bf6776fc4b9284f4e23df0e955a0246724d7f0b8"
    }
  },
  {
    "ts": null,
    "headline": "West Pharmaceutical Services, Inc. (WST) Q3 2025 Earnings Call Transcript",
    "summary": "West Pharmaceutical Services, Inc. (NYSE:WST) Q3 2025 Earnings Call October 23, 2025 8:00 AM EDTCompany ParticipantsJohn Sweeney - Head of Investor...",
    "url": "https://finnhub.io/api/news?id=b2400e3c887b33a4ad485ea1f4db7ff401144a82a5ae2faea5679626d2fcc813",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761232042,
      "headline": "West Pharmaceutical Services, Inc. (WST) Q3 2025 Earnings Call Transcript",
      "id": 137198596,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "WST",
      "source": "SeekingAlpha",
      "summary": "West Pharmaceutical Services, Inc. (NYSE:WST) Q3 2025 Earnings Call October 23, 2025 8:00 AM EDTCompany ParticipantsJohn Sweeney - Head of Investor...",
      "url": "https://finnhub.io/api/news?id=b2400e3c887b33a4ad485ea1f4db7ff401144a82a5ae2faea5679626d2fcc813"
    }
  },
  {
    "ts": null,
    "headline": "Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Oil Surge, Trade Tensions",
    "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively tr",
    "url": "https://finnhub.io/api/news?id=7e8c9e97c609a7031b771bb600093cf31e56af80309189b4d9041d12147b506c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761221237,
      "headline": "Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Oil Surge, Trade Tensions",
      "id": 137198277,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively tr",
      "url": "https://finnhub.io/api/news?id=7e8c9e97c609a7031b771bb600093cf31e56af80309189b4d9041d12147b506c"
    }
  },
  {
    "ts": null,
    "headline": "West Pharmaceutical Services (WST) Tops Q3 Earnings and Revenue Estimates",
    "summary": "West Pharmaceutical (WST) delivered earnings and revenue surprises of +17.37% and +2.43%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=a9f7d7c9f93c6854f34e2d76db100b2643f16fc8c71f83d8ee56e427ef27deeb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761217802,
      "headline": "West Pharmaceutical Services (WST) Tops Q3 Earnings and Revenue Estimates",
      "id": 137218227,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "West Pharmaceutical (WST) delivered earnings and revenue surprises of +17.37% and +2.43%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=a9f7d7c9f93c6854f34e2d76db100b2643f16fc8c71f83d8ee56e427ef27deeb"
    }
  },
  {
    "ts": null,
    "headline": "West Pharmaceutical Services’s (NYSE:WST) Q3 Sales Beat Estimates",
    "summary": "Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 7.7% year on year to $804.6 million. The company’s full-year revenue guidance of $3.07 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $1.96 per share was 16.3% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=6780ca57d7a220a4913e0ff85ac78b1a90c2e4f3b8d79eef332d4bc90237acf3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761214428,
      "headline": "West Pharmaceutical Services’s (NYSE:WST) Q3 Sales Beat Estimates",
      "id": 137218228,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 7.7% year on year to $804.6 million. The company’s full-year revenue guidance of $3.07 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $1.96 per share was 16.3% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=6780ca57d7a220a4913e0ff85ac78b1a90c2e4f3b8d79eef332d4bc90237acf3"
    }
  },
  {
    "ts": null,
    "headline": "West Pharmaceutical: Q3 Earnings Snapshot",
    "summary": "WST) on Thursday reported third-quarter net income of $140 million. The Exton, Pennsylvania-based company said it had net income of $1.92 per share. Earnings, adjusted for restructuring costs and amortization costs, came to $1.96 per share.",
    "url": "https://finnhub.io/api/news?id=1cb7276c9b6bfbb96940baa6631b8a8c9bb92410fb0c6c838d303c465606e994",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761214150,
      "headline": "West Pharmaceutical: Q3 Earnings Snapshot",
      "id": 137218229,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "WST) on Thursday reported third-quarter net income of $140 million. The Exton, Pennsylvania-based company said it had net income of $1.92 per share. Earnings, adjusted for restructuring costs and amortization costs, came to $1.96 per share.",
      "url": "https://finnhub.io/api/news?id=1cb7276c9b6bfbb96940baa6631b8a8c9bb92410fb0c6c838d303c465606e994"
    }
  },
  {
    "ts": null,
    "headline": "West Reports Third-Quarter 2025 Results",
    "summary": "West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the third quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=17e55646158c5792d0e21d48ca85ad826cd4c778fa4c20357d96ed5d2f13ad3d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761213600,
      "headline": "West Reports Third-Quarter 2025 Results",
      "id": 137218230,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the third quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=17e55646158c5792d0e21d48ca85ad826cd4c778fa4c20357d96ed5d2f13ad3d"
    }
  }
]